Nutex Health (NUTX) Earnings Turnaround Leaves The Question Of Whether Shares Are Fully Valued

Earnings-driven spotlight on Nutex Health

Nutex Health (NUTX) moved into focus after reporting second quarter 2026 results, posting net income of US$65.84 million compared to a loss a year earlier, despite lower quarterly revenue.

See our latest analysis for Nutex Health.

Nutex Health’s latest results appear to be feeding into stronger sentiment, with a 1-day share price return of 6.67% and 7-day share price return of 9.93% lifting the stock, even though the 30-day share price return is down 11.88% following a year-to-date share price return of 9.37% and a 1-year total shareholder return of 84.34%, which points to strong longer term momentum.

If Nutex Health’s move has you looking for what else is working in healthcare, it could be a good moment to broaden your search with a dedicated screener for 43 healthcare AI stocks

The quick rebound in Nutex Health after earnings leaves you weighing a fresh entry against waiting for a pullback. Does today’s price already reflect the turnaround, or is there still potential upside based on valuation?

Most Popular Narrative: 31.2% Undervalued

Based on the most followed narrative, Nutex Health’s fair value of $235.50 sits well above the last close at $162.07. This frames the current debate over whether recent earnings justify that gap.

The continued shift toward consumer-driven and ambulatory care is expanding Nutex Health's addressable market, with their micro-hospital and freestanding ER model aligning with preferences for convenient, efficient care, supporting enhanced market share and greater revenue per visit over time. The company's successful navigation of value-based care and risk-based contracts, including rapid expansion of IPAs and population health management capabilities, positions it to benefit from industry reimbursement trends, potentially boosting margins and recurring earnings as the model matures.

Read the complete narrative.

Want to understand why this narrative supports a higher fair value for Nutex Health? The story leans heavily on compounding revenue, rising margins, and a lower earnings multiple in the later years. The combination creates a very different picture from just looking at today’s earnings in isolation.

Result: Fair Value of $235.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Nutex Health’s reliance on arbitration related revenue and past reporting restatements mean that regulatory shifts or control issues could quickly challenge the current undervalued narrative.

Find out about the key risks to this Nutex Health narrative.

Another view on Nutex Health’s valuation

The earlier narrative points to Nutex Health looking 31.2% undervalued against a fair value of $235.50 based on forward earnings and margins. A different lens tells a very different story. Our DCF model puts fair value at $15.75, which makes the current $162.07 share price look expensive rather than cheap.

This gap between earnings-based fair value and the SWS DCF model raises a practical question for you. Which set of assumptions feels closer to how Nutex Health will actually convert earnings into long term cash flows?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nutex Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed sentiment across Nutex Health’s valuation narratives, it helps to move quickly from headlines to hard numbers and come to your own conclusion using the 3 key rewards and 2 important warning signs.

Looking for more Nutex Health investment ideas?

If Nutex Health has sharpened your focus, do not stop here. The right screener can quickly surface fresh opportunities that match what you are looking for next.

• Target potential mispricing by scanning companies that combine quality with attractive valuations through the 52 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with sturdy finances using the solid balance sheet and fundamentals stocks screener (48 results).
• Spot early-stage opportunities with strong fundamentals before the crowd by running the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com